This review synthesizes the current, often conflicting, evidence from observational studies, randomized controlled trials (RCTs), and meta-analyses to evaluate the potential of SGLT2 inhibitors in reducing the risk of cognitive decline, dementia, and other related neurodegenerative disorders in patients with T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.